Filligent Achieves Coveted FFP2:2009 Classification for its Anti-Microbial Respirator in Europe

Share Article

Filligent’s anti-microbial respirator model has received the coveted FFP2 NR EN149:2001 + A1:2009 certification, the highest protection standard of its kind in the world.

Filligent’s anti-microbial respirator model has received the coveted FFP2 NR EN149:2001 + A1:2009 certification, the highest protection standard of its kind in the world. The respirator kills over 99.9% of viruses and bacteria on contact, providing advanced protection for workers at standard prices. The respirator meets the World Health Organization (WHO) standards for protection against pandemic flu and tuberculosis, including HIV-related tuberculosis. It also inactivates H1N1, MRSA, measles and other major pathogens.

In addition to meeting the new EU standards on filtration, the BioMask™ respirator also reduces the risk of cross-contamination of hands and equipment - a serious workplace concern. The respirator has a comfortable and universal fit for most face types. It is self-sanitizing and is made with materials that are non-toxic for humans but lethal to disease-causing pathogens. Customer feedback from doctors and nurses confirms that Filligent’s respirators provide all-day comfort and additional protection to workers when they need it most. The BioMask™ respirators are long-lasting, durable and fold flat for pocket-sized convenience and storage.

The BioMask™ respirator uses a proprietary hydrophilic plastic coating on the outer layer that rapidly absorbs infectious droplets away from the surface of the mask and into the inner layers where disease-causing pathogens are inactivated (killed) by low pH and the natural ions, copper and zinc.

(PRWEB) November 23, 2010 -- Since July 31, 2010, no one in the EU is permitted to sell a respirator unless it meets the new FFP2:2009 standard. These standards are designed to address the inadequacies of electrostatic filtration technology, which until recently was the most popular mechanism for filtration. But studies revealed that products relying on electrostatic filtration can show up to a 10-fold reduction in filtration efficiency within one hour, when the device is used as intended.1 According to the INRS study, “this means that an apparatus classed high efficiency (P3 for example) can change class to average or low efficiency (P2 or P1) during its use… this drop may lead to a considerable impact on the health of users.”*

Melissa Mowbray-d’Arbela, CEO of Filligent, says: “our technology leapfrogs electrostatic filtration to deliver the best medical respiratory protection for workers. It’s part of our continued commitment to those on the frontline.” The BioMask™ respirator is the ultimate protection for those managers who cannot afford for their people to fall sick.

About Filligent
Filligent is a Hong Kong-based, biotech company that develops essential preventive personal health products to help combat disease transmission and initiation. Filligent develops proprietary and advanced biochemical technologies to provide pragmatic health solutions, primarily to address health gaps in developing nations.

BioFriend™ BioMask™ Premium+ respirator: FFP2 NR (EN149:2001 + A1:2009): Cert. No. 6994 A/10/22 PSA:

For purchases in Europe within healthcare and government, please contact Medline Industries:
Customer Service: +(44) 1928 532311
Reception: +(44) 1928 532310
Email: sales(at)medline(dot)co(dot)uk

For purchases within Malaysia, please contact Pharmaniaga:
Sales & Marketing Division
Toll Free: 1 800 388 018
Tel: +(6) 03 3342 9999
ext 293/525

For purchases within Singapore, please contact Weis:
Tel: +(65) 6858 5267
Fax: +(65) 6286-7293
Email: sales(at)weistraders(dot)com

For retail purchases within Germany, Benelux and Scandinavia please contact MBT:
Tel: +(49) 4084 054952
Fax: +(49) 4084 056974
Email: info(at)mbteurope(dot)com

All other enquiries please contact:
Anne English
Senior Marketing Manager
Filligent Limited
Tel: + (852) 2542-2115
Email: anne(dot)english(at)filligent(dot)com

*Lotti, 2003. INRS, 09:16 –18.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Anne English
Visit website